Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial

Figure 4

Incidence rates of adverse event for each month of the study, by age group. No consistent impact of the patients’ age on the overall incidence rate of AEs was observed. Calculation of percentages was based on number of patients not discontinued in the respective month. Patients with multiple adverse events within one month were counted only once.

(a)

(b)

(C)